World-Renowned Athlete Receives Treatment, Featured in Men’s Health Magazine
SUNRISE, FL – Jan. 8, 2018 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced world-renowned fitness expert Ben Greenfield successfully received its stromal vascular fraction treatment for erectile enhancement. Details of the procedure and the results are featured in the January issue of Men’s Health, on newsstands now.
Greenfield, whose experience following the treatments includes more frequent erections and penile enlargement, received his first of two treatments at the USRM clinic in Sunrise, Florida.
Stromal vascular fraction treatments, or autologous stem cell treatments harvested from the patient’s own fat, could provide healthier alternatives to use of pharmaceuticals for erectile enhancement and dysfunction (ED) — a market that is estimated to be more than $4 billion annually and has slowed in growth due to toxic side effects from pharmaceuticals currently on the market, according to a report by Grand View Research published in July 2016. Greenfield, who is a self-professed ‘biohacker,’ sought treatment as part of his ongoing exploration of ‘biohacking’ and penile enhancement. “My drive to discover cutting-edge therapies is what led me to U.S. Stem Cell, and my results certainly convinced me of the validity of this treatment,” said Greenfield. “The opportunity to dictate our own therapies to enhance performance in all arenas of health is an empowering part of physical performance, and it is a demonstration that regenerative medicine is here now.”
Stromal vascular fraction involves using USRM’s proprietary AdipoCellTM kit to help isolate a patient’s own stem cells from the fat cells. Studies of stromal vascular fraction’s used in ED therapy are starting to emerge, as is documented in a scientific paper featured in EBioMedicine’s January 2017 issue.
“Autologous stem cell therapy is rapidly entering the arena of mainstream regenerative medicine, as is exemplified by its acceptance, use and promotion by cutting edge biohackers and fitness experts like Mr. Greenfield,” said Dr. Kristin Comella, USRM’s Chief Science Officer. “As regenerative stem cell therapy continues to expand into specialized markets, we look forward to broadening our application for these voluntary procedures.”
Greenfield, who was voted in 2013 and 2014 as one of the world’s top 100 most influential people in health and fitness by Greatist, coaches top CEO’s, chefs, biohackers, endurance competitors, and professional athletes from the UFC, NHL, NBA, NFL and beyond – all while advising and investing in top companies in the health, fitness and nutrition industries. He was voted in 2008 as Personal Trainer of the Year by the National Strength and Conditioning Association (NSCA), and is a regular contributor to Huffington Post. He is also the CEO of Kion Health and hosts the highly popular Ben Greenfield Fitness podcast, one of the top-ranked health and fitness podcasts in iTunes. He has a bachelor’s degree and master’s degree from University of Idaho in sports science and exercise physiology and personal training, plus strength and conditioning certifications from the NSCA.
“Last year was about restructuring debt and streamlining our financials in order to position ourselves in 2018 for these kinds of opportunities,” said Mike Tomas, USRM’s Chief Executive Officer. “We look forward to continuing to explore the application of stromal vascular fraction treatments for a wide variety of voluntary procedures which is being driven by market demand for more holistic, autologous therapies.”
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell TM , as well as veterinary stem cell training and stem cell banking and creation and management of stem cell clinics. To management’s knowledge, USRM has completed more clinical treatments than any other stem cell company in the world in the past 20 years, and has certified more than 700 physicians and veterinarians in autologous stem cell therapy worldwide.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward- looking statements and represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company’s business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.